Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett’s esophagus

Robert J. Korst, MD, a,b Sobeida Santana-Joseph, MSN, a,b John R. Rutledge, MAS, a Arthur Antler, MD, c Vivian Bethala, MD, c Anthony DeLillo, MD, c Donald Kutner, DO, c Benjamin E. Lee, MD, a,b Haleh Pazwash, MD, c Robert H. Pittman, MD, c Michael Rahmin, MD, c and Mitchell Rubinoff, MD c

Objective: Radiofrequency ablation can eradicate Barrett’s esophagus successfully in the majority of cases. We sought to determine (1) how often intestinal metaplasia is detected during follow-up endoscopy after successful ablation and (2) patterns of persistent/recurrent intestinal metaplasia.

Methods: Patients ablated successfully during a phase II clinical trial of radiofrequency ablation for Barrett’s esophagus were followed using endoscopic surveillance according to a defined protocol. Systematic biopsies were performed in all patients throughout the neosquamous epithelium as well as at the gastroesophageal junction, and patterns of recurrent or persistent intestinal metaplasia were documented.

Results: Fifty-three patients were ablated successfully during this single-institution clinical trial. A total of 151 follow-up endoscopies were performed (range, 1-5 endoscopies per patient) and 2492 biopsies were obtained, of which 604 (24%) were from the gastroesophageal junction. The median follow-up period was 18 months (range, 3-50 months). Recurrent/persistent intestinal metaplasia was detected in 14 patients (26%) in 3 distinct patterns: endoscopically invisible intestinal metaplasia underneath the neosquamous epithelium (buried glands) in 3 patients, visible recurrence in the tubular esophagus in 3 patients, and intestinal metaplasia of the gastroesophageal junction (with a squamous-lined tubular esophagus) in 10 patients. Dysplasia or cancer was not detected in any patient during the follow-up period.

Conclusions: Recurrent/persistent intestinal metaplasia after successful radiofrequency ablation of Barrett’s esophagus is relatively common. This finding has implications for the continued surveillance of patients who are ablated successfully. (J Thorac Cardiovasc Surg 2013;145:1529-34)
METHODS
Clinical Trial
A phase II clinical trial of RFA for BE was performed between 2007 and 2011 at a single institution after approval by the institutional review board. All patients signed informed consent. Barrett’s esophagus was defined as an esophageal columnar segment >3 cm in length regardless of whether IM was detected by biopsy or an esophageal columnar segment <3 cm with biopsy-proved IM. Patients with IM of the gastroesophageal junction without a columnar-lined esophagus were not included in this trial. The initial success rates of eradicating BE were published previously, along with the clinical trial details.\(^1\) Success was defined as establishment of squamous epithelium (confirmed histologically) throughout the tubular esophagus as visualized using both white light and narrow-band imaging. Two months after the last ablation, all patients underwent a single follow-up endoscopy, during which the success of the procedure was established. This initial follow-up endoscopy was not considered part of the follow-up protocol. As part of the clinical trial, all successfully ablated patients underwent scheduled endoscopic follow-up according to a rigorous protocol depending on patients’ preablative histologic diagnosis, as shown in Table 1. During each endoscopy, inspection of the mucosa was performed using white light and narrow-band imaging, and systematic biopsies were performed. Successfully ablated patients who had IM discovered at the gastroesophageal junction (cardia) at follow-up endoscopy did not undergo further ablation because they did not meet the definition of BE established when the protocol was written.

After successful RFA, a proton pump inhibitor (PPI) dose was maintained at a level that provided relief from gastroesophageal reflux symptoms. The performance of hiatal hernia repair and fundoplication was left up to the discretion of the principal investigator (R.J.K.), but was mainly symptom directed.

Biopsy Protocol
At each endoscopic examination, a systematic biopsy protocol was followed in all patients, which included 4 quadrant biopsies, performed at 1 to 2-cm intervals throughout the entire segment of neosquamous epithelium using jumbo biopsy forceps (Radial jaw 4; Boston Scientific, Natick, Mass). In addition, 4 quadrant biopsies were performed routinely just inferior to the “new” squamocolumnar junction (the gastroesophageal junction). If, at the time of endoscopic examination, a significant region of mucosal irregularity was identified in a columnar-lined area, it was removed using endoscopic mucosal resection. Biopsy specimens were fixed in formalin, embedded in paraffin, cut, and stained with hematoxylin and eosin.

Data Collection
Data collected for the current analysis included patient demographics, length of BE, size of hiatal hernia, number of post-RFA endoscopies, number of post-RFA biopsies, length of follow-up after the last ablation, recurrence of BE, the presence of buried glands, and the presence of IM with or without dysplasia of the gastroesophageal junction. Recurrent BE was defined as the recurrence of a grossly visible columnar lining within the tubular esophagus, with histologic confirmation of IM. Buried glands were defined as glandular epithelium present underneath stratified squamous epithelium.

Statistical Analysis
Follow-up data were analyzed using the Kaplan-Meier methodology, and the probability of being recurrence free was plotted. IBM-SPSS Statistics software (version 19; Armonk, NY) was used for the statistical analysis.

RESULTS
Patient Characteristics
Fifty-three patients were treated successfully using RFA for BE on this phase II protocol. There were 37 males and 16 females, with a median age of 59 years (age range, 24-85 years). The median length of the initial columnar segment was 3 cm (range, 1-16 cm) and the median hiatal hernia size was 2 cm (range, 0-8 cm). Forty patients (75\%) had nondysplastic BE, whereas 4 patients (8\%) had low-grade dysplasia, 4 (8\%) had high-grade dysplasia, and 4 (8\%) were read as indefinite for dysplasia. One patient had a T1a adenocarcinoma removed using endoscopic mucosal resection prior to RFA for the remaining BE. All patients had IM present in their columnar segments prior to ablation.

Endoscopic Follow-up
A total of 151 follow-up endoscopies were performed on this cohort of 53 patients (median, 3 per patient; range, 1-5 per patient) and a total of 2492 biopsies were evaluated histologically (median, 36 per patient; range, 8-156 per patient). Biopsies obtained from the gastroesophageal junction totaled 604 (24\% of total biopsies). The median follow-up period was 18 months (range, 3-50 months). Figure 1 demonstrates follow-up compliance for the 51 patients who entered the follow-up protocol. Two patients have been ablated successfully but have not yet undergone their first endoscopy in the follow-up protocol. Recurrent and/or persistent IM was detected at some point during the follow-up period in 14 of 53 successfully ablated patients (26\%). Figure 2 demonstrates the probability of being recurrence free based on the follow-up data.

Buried Glands
Buried glands were detected at some point after successful ablation in 3 biopsies from 3 patients (6\% of patients, 0.2\% of biopsies from the tubular esophagus). All 3 patients had at least 3 post-RFA endoscopies, and in no patient was dysplasia detected. The clinical characteristics of these 3 patients are displayed in Table 2.

Recurrence of Barrett’s Esophagus
Recurrent BE was detected endoscopically and confirmed histologically in 3 patients (6\%). In all 3 instances, new tongues of columnar lining (1-2 cm in length) were visualized in the presence of active esophagitis, and biopsies confirmed IM, without dysplasia. After their successful initial ablation,
all 3 patients had lowered their PPI dose to the dose they were taking prior to ablation. The clinical characteristics of these 3 patients are shown in Table 3.

Intestinal Metaplasia of the Gastroesophageal Junction

After successful ablation, 10 patients (19%) were diagnosed with IM of the gastroesophageal junction, despite having a squamous-lined tubular esophagus. Dysplasia was not detected in any patient. Table 4 presents the clinical characteristics and persistence of IM of the gastroesophageal junction in these 10 patients. Nine of these patients were ablated initially for nondysplastic BE, with the 10th patient having high-grade dysplasia prior to ablation.

Postablation Gastroesophageal Reflux Control

After successful ablation, 15 patients (28%) decreased their PPI dose down to the level they were taking prior to ablation. Thirty-four patients (64%) were maintained on the elevated PPI dose used for ablation. Four patients (8%) underwent hiatal hernia repair and fundoplication.

DISCUSSION

Barrett’s esophagus is a premalignant condition of the esophagus caused by chronic gastroesophageal reflux. The risk of developing adenocarcinoma of the esophagus in the setting of BE is not clear, but estimates have ranged from 0.1% to 0.5% per patient, per year of follow-up, with the risk being cumulative over time.16 As a result, ablative techniques have been developed aimed at eliminating the columnar lining and replacing it with stratified squamous epithelium. We have published previously our initial results with eradication of BE using RFA from a phase II clinical trial at our institution conducted between 2007 and 2011, with an intent-to-treat success rate of 78% (91% “per protocol” success rate).12 The current analysis addresses the follow-up of the successfully ablated patients from this clinical trial, focusing on the persistence and recurrence of IM.

Intestinal Metaplasia in the Postablation Tubular Esophagus

In the current study, IM of the tubular esophagus detected during the follow-up period took 2 forms: buried glands...
Buried glands after RFA are uncommon, and have been found in less than 10% of patients enrolled in clinical trials evaluating RFA. Results from the clinical trial reported herein corroborate this finding, with only 6% of successfully ablated patients demonstrating this phenomenon at some point during their follow-up. Interestingly, all biopsies showing buried glands were located a substantial distance away from any visible columnar mucosa prior to ablation.

Buried glands after RFA are uncommon, and have been found in less than 10% of patients enrolled in clinical trials evaluating RFA. Results from the clinical trial reported herein corroborate this finding, with only 6% of successfully ablated patients demonstrating this phenomenon at some point during their follow-up. Interestingly, all biopsies showing buried glands were located a substantial distance away from any visible columnar mucosa prior to ablation.

### Table 2. Clinical features of patients with buried glands found after successful ablation

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Preablation histology</th>
<th>Initial BE length, cm</th>
<th>Level of buried glands, cm*</th>
<th>Level of “new” squamocolumnar junction, cm*</th>
<th>Timing of positive endoscopy†</th>
</tr>
</thead>
<tbody>
<tr>
<td>007</td>
<td>HGD</td>
<td>10</td>
<td>36</td>
<td>40</td>
<td>N</td>
</tr>
<tr>
<td>006</td>
<td>Nondysplastic</td>
<td>16</td>
<td>38</td>
<td>42</td>
<td>N</td>
</tr>
<tr>
<td>017</td>
<td>Nondysplastic</td>
<td>5</td>
<td>26</td>
<td>30</td>
<td>Y</td>
</tr>
</tbody>
</table>

BE, Barrett’s esophagus; HGD, high-grade dysplasia; N, buried glands not detected; Y, buried glands detected; NP, endoscopy at designated time interval was not performed; —, follow-up time point has not yet been reached. *Distance from incisors. †Postablation endoscopies were performed according to the schedule in Table 1.

### Table 3. Clinical features of patients with recurrent Barrett’s esophagus with intestinal metaplasia

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Preablation histology</th>
<th>Initial BE length, cm</th>
<th>Size of hiatal hernia, cm*</th>
<th>Timing of positive endoscopy†</th>
</tr>
</thead>
<tbody>
<tr>
<td>023</td>
<td>Nondysplastic</td>
<td>4</td>
<td>4</td>
<td>N</td>
</tr>
<tr>
<td>053</td>
<td>Nondysplastic</td>
<td>2</td>
<td>5</td>
<td>N</td>
</tr>
<tr>
<td>028</td>
<td>Nondysplastic</td>
<td>5</td>
<td>8</td>
<td>Y</td>
</tr>
</tbody>
</table>

BE, Barrett’s esophagus; N, recurrence not detected; NP, endoscopy at designated time interval was not performed; Y, recurrence detected; —, follow-up time point has not yet been reached. *Distance between the top of the gastric folds and the crural pinch. †Postablation endoscopies were performed according to the schedule in Table 1.

(endothecically invisible subsquamous IM) as well as recurrent tongues of endoscopically visible columnar lining. Buried glands have been reported in patients with BE both before and after attempts at ablation, regardless of the ablative technique used.14,17 In the presence of BE, buried glands are usually associated with squamous islands located within the columnar segment.1,7 Indeed, in the randomized trial of RFA for dysplastic BE, Shaheen and colleagues1 found buried glands in 25.2% of patients prior to treatment randomization. In contrast, buried glands were not detected in any patient from the current study prior to ablation, perhaps because the protocol did not mandate routine sampling of the squamous mucosa prior to ablation.

Buried glands after RFA are uncommon, and have been found in less than 10% of patients enrolled in clinical trials evaluating RFA. Results from the clinical trial reported herein corroborate this finding, with only 6% of successfully ablated patients demonstrating this phenomenon at some point during their follow-up. Interestingly, all biopsies showing buried glands were located a substantial distance away from any visible columnar mucosa (Table 2). Although buried glandular tissue has been reported to harbor dysplasia and even malignancy,14 this was not the case in the current study.

**Intestinal Metaplasia of the Gastroesophageal Junction**

The most common circumstance in which IM was detected after successful RFA of the tubular esophagus in the current trial was immediately inferior to the “new” squamocolumnar junction (cardia of stomach). Because the protocol mandated the routine that 4 quadrant biopsies be acquired in this region using jumbo forceps, every patient’s gastroesophageal junction was evaluated during every postablation endoscopic examination. There is a paucity of prospective, published data addressing this phenomenon because routine sampling of this area was not performed in several of the clinical trials evaluating RFA for BE.1,2,6 In the prospective trials in which it was evaluated, IM of the gastroesophageal junction was not as frequent as described herein (19% of successfully ablated patients), ranging from 0% to 18% of patients.3-5 The 19% frequency described in the current study, however, supports the retrospective analysis performed by Vaccaro and colleagues,15 in which IM of the gastroesophageal junction was detected in 11 of 49 successfully ablated patients (22%). The significance of IM of the gastroesophageal junction detected in patients in whom the tubular esophagus has been ablated successfully using RFA is unknown. It is unclear whether these patients developed recurrent IM in this area or whether this finding represents persistent IM, because the cardia was not ablated in this trial. Intestinal
TABLE 4. Clinical features of patients with intestinal metaplasia of the gastroesophageal junction detected after successful radiofrequency ablation

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Preablation histology</th>
<th>Initial BE length, cm</th>
<th>Size of hiatal hernia, cm*</th>
<th>Timing of positive endoscopy†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st</td>
</tr>
<tr>
<td>009</td>
<td>Nondysplastic</td>
<td>1</td>
<td>0</td>
<td>N</td>
</tr>
<tr>
<td>036</td>
<td>Nondysplastic</td>
<td>1</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>042</td>
<td>Nondysplastic</td>
<td>6</td>
<td>4</td>
<td>Y</td>
</tr>
<tr>
<td>024</td>
<td>Nondysplastic</td>
<td>2</td>
<td>0</td>
<td>N</td>
</tr>
<tr>
<td>059</td>
<td>Nondysplastic</td>
<td>2</td>
<td>3</td>
<td>Y</td>
</tr>
<tr>
<td>069</td>
<td>Nondysplastic</td>
<td>3</td>
<td>3</td>
<td>Y</td>
</tr>
<tr>
<td>007</td>
<td>HGD</td>
<td>10</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>081</td>
<td>Nondysplastic</td>
<td>3</td>
<td>0</td>
<td>Y</td>
</tr>
<tr>
<td>094</td>
<td>Nondysplastic</td>
<td>2</td>
<td>2</td>
<td>Y</td>
</tr>
<tr>
<td>006</td>
<td>Nondysplastic</td>
<td>16</td>
<td>2</td>
<td>Y</td>
</tr>
</tbody>
</table>

*Size of hiatal hernia measured by endoscopy. **Timing of positive endoscopy: 1st, first positive; 2nd, second positive; 3rd, third positive; 4th, fourth positive; 5th, fifth positive.

BE, Barrett’s esophagus; N, intestinal metaplasia of the gastroesophageal junction is not detected; Y, intestinal metaplasia of the gastroesophageal junction is detected; —, follow-up time point has not yet been reached; HGD, high-grade dysplasia; NP, endoscopy at designated time interval was not performed. *Distance between the top of the gastric folds and the crural pinch. †Postablation endoscopies were performed according to the schedule in Table 1.

The detection of IM after successful RFA of BE is common, occurring in 26% of individuals treated with this technology. Although the incidence of buried glands and endoscopically visible recurrence of IM is uncommon, the presence of IM of the gastroesophageal junction is encountered more frequently—the significance of which is unknown—but has implications for further surveillance after successful RFA.

CONCLUSIONS

The detection of IM after successful RFA of BE is common, occurring in 26% of individuals treated with this technology. Although the incidence of buried glands and endoscopically visible recurrence of IM is uncommon, the presence of IM of the gastroesophageal junction is encountered more frequently—the significance of which is unknown—but has implications for further surveillance after successful RFA.

References


